CSF biomarkers of AD in MCI patients


The goal of finding clinically useful biomarkers to identify MCI patients at risk of developing Alzheimer’s disease has proved elusive with conflicting results reported by different centres. In Sweden, a large multicentre study has investigated the accuracy of CSF beta-amyloid(1-42), total tau protein (T-tau), and tau phosphorylated at position threonine 181 (P-tau) (Mattsson et al. JAMA 2009; 302: 385-393).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page